GF/B23/DP22
Approved by the Board on: 12 May 2011
Expediting transition to fixed-dose combinations of artemisinin-based combination therapies (ACTs)
- In accordance with Board Decision Point GF/B22/DP11, the Board notes that the Market Dynamics and Commodities Ad-hoc Committee ("MDC"), in line with WHO guidance, has presented recommendations to the Board regarding appropriate transition by recipients of Global Fund financing to the use of fixed-dose combinations (FDCs) of artemisinin-based combination therapies (ACTs).
- The Board determines that once the Secretariat has decided in its discretion that there are at least two FDC Finished Pharmaceutical Products of an ACT Formulation ("FDC ACT") for the treatment of uncomplicated malaria that comply with the Global Fund Quality Assurance Policy for Pharmaceutical Products (as approved by the Board in accordance with Decision Point GF/B22/DP9) ("QA Policy"), and each FDC ACT is considered "available" as defined in Section 8 of the QA Policy,
then,
(a) the Global Fund shall notify Principal Recipients in writing and on the Global Fund website that it has made such a decision (the date of such notification being the "Notification Date"); and
(b) from 90 days after the Notification Date, Global Fund financing for that ACT formulation can only be used to procure FDCs of that ACT formulation. - For recipients of Global Fund financing that have not procured FDC ACTs using Global Fund financing prior to the Notification Date, a grace period of up to one year to transition to FDC ACTs can be applied on a case-by-case basis, at the discretion of the Secretariat. The Secretariat, in collaboration with partners, will facilitate the provision of support to recipients of Global Fund financing to conduct an effective and timely transition to FDC ACTs where necessary and appropriate.
Budgetary Implications
This decision does not have material budgetary implications for the Operating Expense Budget.